L3MBTL2抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Mouse thymus tissue lysate, Primary antibody: P10219(L3MBTL2 Antibody) at dilution 1/1000, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 35 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P10219(L3MBTL2 Antibody) at dilution 1/70. (Original magnification: ×200)    

  
  

L3MBTL2 (Lethal(3)malignant brain tumor-like 2) is a chromatin-associated protein belonging to the MBT (malignant brain tumor) domain-containing protein family, which is implicated in epigenetic regulation. It recognizes and binds to mono- or dimethylated lysine residues on histones (e.g., H4K20me1/2), a feature linked to transcriptional repression and chromatin compaction. L3MBTL2 functions as a transcriptional repressor, often acting in concert with polycomb repressive complexes (PRCs) or other chromatin modifiers to regulate gene expression, genomic stability, and cellular differentiation. Its role in suppressing inappropriate transcription has been associated with tumor suppression, as dysregulation of L3MBTL2 is observed in certain cancers.

Antibodies targeting L3MBTL2 are essential tools for studying its localization, interactions, and mechanistic roles in chromatin biology. They are widely used in techniques like Western blotting, immunoprecipitation (IP), chromatin immunoprecipitation (ChIP), and immunofluorescence to investigate its involvement in DNA repair, cell cycle regulation, and developmental processes. Commercially available L3MBTL2 antibodies are typically validated for specificity against its unique MBT domains or other epitopes, enabling researchers to distinguish it from related family members (e.g., L3MBTL1 or MBTD1). Studies using these antibodies have highlighted L3MBTL2's contribution to maintaining heterochromatin integrity and its potential as a biomarker or therapeutic target in diseases marked by epigenetic dysregulation.